

PROVIDER Update



CONTRACTUAL | OCTOBER 24, 2022 | UPDATE 22-897 | 2 PAGES

Know What's New and Changing: 2023 Prior Authorization List

Drugs that require prior authorization now and other changes that start January 1, 2023

The below medical benefit medications require prior authorization (PA) for all lines of business per new HCPCS codes issued by the Centers for Medicare & Medicaid Services effective October 1, 2022.

Code	Description
C9142	Injection, bevacizumab-maly, biosimilar, (Alymsys®), 10 mg
J1302	Injection, sutimlimab-jome, 10 mg
J1932	Injection, lanreotide, (Cipla), 1 mg
J2777	Injection, faricimab-svoa, 0.1 mg
J9274	Injection, tebentafusp-tebn, 1 mcg
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Q2056	Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q5125	Injection, filgrastim-ayow, biosimilar, (Releuko®), 1 mcg

Go online for current PA requirements

Follow the steps below to find out if any procedures, services or equipment need PA:

- 1 Go to provider.healthnet.com.
- 2 Before logging in, select *Working with Health Net > Additional Resources > Services Requiring Prior Authorization*.
- 3 After logging in, select *Working with Health Net > Contractual > Services Requiring Prior Authorization*.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals/Clinics
- Ancillary Providers
- Community Supports (CS) Providers
- Enhanced Care Management (ECM) Providers

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter EPO
 - Ambetter HSP
- Employer Group
 - HMO/POS/HSP
 - EPO
 - PPO
- Medicare Advantage (HMO/PPO)
- (Wellcare By Health Net)
- Cal MediConnect (Los Angeles/San Diego)
- Medi-Cal
 - Kern
 - Los Angeles– (LA-DHS)
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com
800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

2023 New services for community supports and adding to outpatient pharmaceuticals

Health Net* is making the changes shown below to the prior authorization (PA) requirements for Los Angeles County Department of Health Services (LA-DHS) hospitals and clinics.

Requirement	Comments
Additions, effective January 1, 2023	
Community Supports <ul style="list-style-type: none">Community transition services/nursing facility transition to a homeDay habilitationNursing facility transition/diversion to assisted living facilitiesPersonal care and homemaker servicesRespite servicesShort-term post-hospitalization housing	Refer to the CalAIM Resources for Providers page at healthnet.com > <i>Providers</i> > <i>CALAIM RESOURCES</i> .
Outpatient Pharmaceuticals (submitted under Medical Plan)	Histrelin acetate
Changes, effective January 1, 2023	
Avsola®	Avsola is no longer a preferred biosimilar to Remicade®.
Bevacizumab agents	Now require authorization for all providers – previously limited to non-ophthalmologist only.
Long-term care facility admissions	No longer limited to Los Angeles residents under the Medi-Cal benefit manager.

Additional information

If you have questions regarding the information contained in this update, contact the Health Net Medi-Cal Provider Services Center at 800-675-6110.